Nancy Christmas, MD
Retina Specialist · Denver, CONPI 1619927456
Payments from drug & device makers
Across 282 payments — averaging $2749.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$763K
- US Retina LLC$10K
- AbbVie$971
- Regeneron Healthcare Solutions, Inc.$312
- Astellas Pharma US Inc$148
- Novartis$95
- plus $451 from 8 others
What the payments were for
- Grants$831%
- Food & beverage$1,20310%
- Education$7506%
- Ownership interest$10,28683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 211 | $763,171 |
| US Retina LLC | 8 | $10,286 |
| AbbVie(2 entities) | 16 | $971 |
| Regeneron Healthcare Solutions, Inc. | 13 | $312 |
| Astellas Pharma US Inc | 8 | $148 |
| Novartis | 6 | $95 |
| Biogen | 5 | $84 |
| Genentech USA, Inc. | 5 | $76 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Bausch & Lomb Americas Inc. | 3 | $63 |
| Coherus Oncology, Inc. | 2 | $51 |
| Alimera Sciences, Inc. | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Harrow Eye, LLC | 1 | $18 |
How this compares
$775,433 in reported general payments places this provider in the 80th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 58 | $2,354 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $275 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Denver
- Brian JoondephDenver$1.6M
- Alan KimuraDenver$546K
- Jesse SmithDenver$23K
- Miriah TeeterDenver$3K
- Diana ReevesDenver$3K
- Mariana HarasawaDenver$332
- Sara HaugDurango$9.5M
- James LuuColorado Springs$2.9M
- Mimi LiuEnglewood$2.2M
- Murtaza AdamParker$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.